Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Capital Expenditures (2016 - 2025)

PAVmed has reported Capital Expenditures over the past 5 years, most recently at $14000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 250.0% year-over-year to $14000.0; the TTM value through Dec 2025 reached $31000.0, down 86.64%, while the annual FY2025 figure was $31000.0, 43.64% down from the prior year.
  • Capital Expenditures for Q4 2025 was $14000.0 at PAVmed, up from $3000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $1.3 million in Q4 2021 and troughed at $3000.0 in Q2 2024.
  • A 5-year average of $175315.8 and a median of $35000.0 in 2021 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: surged 1494.44% in 2022 and later crashed 97.81% in 2024.
  • Year by year, Capital Expenditures stood at $1.3 million in 2021, then crashed by 76.66% to $298000.0 in 2022, then crashed by 38.59% to $183000.0 in 2023, then crashed by 97.81% to $4000.0 in 2024, then skyrocketed by 250.0% to $14000.0 in 2025.
  • Business Quant data shows Capital Expenditures for PAVM at $14000.0 in Q4 2025, $3000.0 in Q3 2025, and $8000.0 in Q2 2025.